December 6, 2023
Guest: Mikkael A. Sekeres, M.D., M.S.
Listen Time: 30m
Only a few decades ago, blood cancer patients faced a grim five-year survival rate. Today, that rate has more than doubled thanks to scientific innovation and targeted therapies that disrupt the growth and survival of cancer cells. But the battle is far from over.
Because of complex genetic mutations, treating blood cancers is particularly challenging and requires precise diagnoses and specialized therapies. In the intricate world of leukemia and myeloid dysplastic syndrome, each breakthrough achieved through clinical trials brings scientists and clinicians a step closer to transforming future standards of care.
